MGD 009

Drug Profile

MGD 009

Alternative Names: B7-H3 x CD3; MGD009

Latest Information Update: 09 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD276 protein inhibitors; CD3 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Mar 2016 Pharmacokinetics and pharmacodynamics data from a preclinical studies in Solid tumours released by MacroGenics
  • 01 Sep 2015 Phase-I clinical trials in Solid tumours (Late-stage, Metastatic) in USA (Parenteral) (NCT02628535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top